Prestige Consumer Healthcare Inc Revenue Growth Rates (PBH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Prestige Consumer Healthcare Inc   (NYSE: PBH)
 

PBH's Revenue Growth by Quarter and Year

Prestige Consumer Healthcare Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PBH Revenue (in millions $) FY 2027 FY 2026 FY 2025 FY 2024
4th Quarter March -
3rd Quarter December -
2nd Quarter September -
1st Quarter June 265.71
FY 265.71

PBHs Annual Revenue
Prestige Consumer Healthcare Inc 's Revenue in the fiscal year 2026 $ 1,088.58 millions
Prestige Consumer Healthcare Inc 's Revenue in the fiscal year 2025 $ 1,137.46 millions
Prestige Consumer Healthcare Inc 's Revenue in the fiscal year 2024 $ 1,124.45 millions
Prestige Consumer Healthcare Inc 's Revenue in the fiscal year 2023 $ 1,127.73 millions
Prestige Consumer Healthcare Inc 's Revenue in the fiscal year 2022 $ 1,086.81 millions




PBH Revenue first quarter 2027 Y/Y Growth Comment
Prestige Consumer Healthcare Inc reported Revenue growth of 6.57% year on year in the first quarter 2027, to $ 265.71 millions, this is lower than Prestige Consumer Healthcare Inc 's recent average Revenue increase of 10.25%.

Looking into first quarter 2027 results within Major Pharmaceutical Preparations industry 122 other companies have achieved higher Revenue growth. While Prestige Consumer Healthcare Inc ' s Revenue increase of 6.57% ranks overall at the positon no. 2746 in the first quarter 2027.


PBH Revenue ( Y/Y Growth %) 2027
 2026 2025 2024
4th Quarter March - -4.95 % 6.91 % -2.82 %
3rd Quarter December - -2.3 % 2.88 % 2.33 %
2nd Quarter September - -3.46 % -0.92 % -1.12 %
1st Quarter June 6.57 % -6.62 % -4.18 % 0.58 %
FY   - -4.3 % 1.16 % -

Financial Statements
Prestige Consumer Healthcare Inc 's first quarter 2027 Revenue $ 265.71 millions PBH's Income Statement
Prestige Consumer Healthcare Inc 's first quarter 2026 Revenue $ 249.33 millions Quarterly PBH's Income Statement


PBH Revenue (Quarter on Quarter Growth %)

 2027
 2026 2025 2024
4th Quarter March - -0.38 % 2.4 % -1.46 %
3rd Quarter December - 3.58 % 2.35 % -1.43 %
2nd Quarter September - 9.73 % 6.13 % 2.64 %
1st Quarter June -5.88 % -16.05 % -3.89 % -2.52 %
FY (Year on Year)   - -4.3 % 1.16 % -


Back to PBH Growth rate Comparisons >> Back to PBH Growth rate Comparisons >>


Revenue first quarter 2027 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #123
Healthcare Sector #391
Overall #2746

Revenue Y/Y Growth Statistics
High Average Low
74.1 % 10.25 % -8.15 %
(Dec 31 2012)   (Jun 30 2019)
Revenue first quarter 2027 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #123
Healthcare Sector #391
Overall #2746
Revenue Y/Y Growth Statistics
High Average Low
74.1 % 10.25 % -8.15 %
(Dec 31 2012)   (Jun 30 2019)

Revenue by Quarter for the Fiscal Years 2024, 2025, 2026, 2027

Prestige Consumer Healthcare Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
142.43 % 3.6 % -56.62 %
(Jun 30 2011)  


PBH's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2027 Prestige Consumer Healthcare Inc disclosed decline in Revenue from the fourth quarter by -5.88% to $ 265.71 millions, from $ 282.30 millions achived in the previous reporting period.

But that's not important problem, as Prestige Consumer Healthcare Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 109 other companies have achieved higher Revenue quarter on quarter growth. While Prestige Consumer Healthcare Inc 's Revenue growth quarter on quarter, overall rank is 2568.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #110
Healthcare Sector #319
Overall #2568
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #110
Healthcare Sector #319
Overall #2568
Revenue Q/Q Growth Statistics
High Average Low
142.43 % 3.6 % -56.62 %
(Jun 30 2011)  


PBH's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2027 Prestige Consumer Healthcare Inc disclosed decline in Revenue from the fourth quarter by -5.88% to $ 265.71 millions, from $ 282.30 millions achived in the previous reporting period.

But that's not important problem, as Prestige Consumer Healthcare Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 109 other companies have achieved higher Revenue quarter on quarter growth. While Prestige Consumer Healthcare Inc 's Revenue growth quarter on quarter, overall rank is 2568.


Prestige Consumer Healthcare Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1,104.96 $ 1,088.58 $ 1,103.29 $ 1,109.97 $ 1,119.77
Y / Y Revenue Growth (TTM) -1.32 % -4.3 % -1.34 % -0.02 % 0.63 %
Year on Year Revenue Growth Overall Ranking # 2545 # 2057 # 2336 # 1124 # 1819
Seqeuential Revenue Change (TTM) 1.5 % -1.33 % -0.6 % -0.88 % -1.56 %
Seq. Revenue Growth (TTM) Overall Ranking # 2746 # 1999 # 1570 # 1054 # 1792


Cumulative Revenue growth Comment
Prestige Consumer Healthcare Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Prestige Consumer Healthcare Inc 's annual Revenue decline would be -1.32% year on year to $1,105 millions.

In the Healthcare sector 371 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2057 to 2545.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 372
Overall # 2545

Revenue TTM Y/Y Growth Statistics
High Average Low
74.1 %
 10.25 %
-8.15 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 391
S&P 500 # 2746
Cumulative Revenue growth Comment
Prestige Consumer Healthcare Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Prestige Consumer Healthcare Inc 's annual Revenue decrease would be -1.32% year on year to $1,105 millions.

In the Healthcare sector 371 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2057 to 2545.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 372
Overall # 2545

Revenue TTM Y/Y Growth Statistics
High Average Low
74.1 %
10.25 %
-8.15 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 391
S&P 500 # 2746




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PBH's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Harrow Inc 11.26%$ 11.256 millions
Rapid Micro Biosystems Inc 10.91%$ 10.906 millions
Livanova Plc10.80%$ 10.797 millions
Cerus Corporation10.52%$ 10.517 millions
Interpace Biosciences Inc 10.33%$ 10.331 millions
Warby Parker Inc 10.25%$ 10.253 millions
Neuronetics Inc 10.25%$ 10.249 millions
Elanco Animal Health Incorporated10.23%$ 10.234 millions
Quest Diagnostics Inc10.21%$ 10.214 millions
Gilead Sciences Inc 10.18%$ 10.181 millions
Lifeloc Technologies Inc 10.16%$ 10.163 millions
Abbvie Inc 10.16%$ 10.160 millions
Concentra Group Holdings Parent Inc 10.03%$ 10.030 millions
Lemaitre Vascular Inc 10.02%$ 10.017 millions
Amneal Pharmaceuticals Inc 9.93%$ 9.934 millions
Merit Medical Systems Inc9.79%$ 9.792 millions
Idexx Laboratories Inc9.73%$ 9.728 millions
Lenz Therapeutics Inc 9.72%$ 9.720 millions
Encompass Health Corporation9.58%$ 9.584 millions
Trisalus Life Sciences Inc 9.57%$ 9.567 millions
Amgen Inc 9.53%$ 9.533 millions
Sotera Health Company9.45%$ 9.452 millions
Illumina Inc 9.44%$ 9.443 millions
Stryker Corp9.42%$ 9.415 millions
International Stem Cell Corporation9.32%$ 9.318 millions
Cytosorbents Corporation9.29%$ 9.292 millions
Resmed Inc 9.22%$ 9.222 millions
Fate Therapeutics Inc 9.18%$ 9.177 millions
Bausch and Lomb Corp9.08%$ 9.077 millions
Pacs Group Inc 9.07%$ 9.071 millions


About Prestige Consumer Healthcare Inc Revenue Growth Rates (PBH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Prestige Consumer Healthcare Inc (CIK 1295947).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001295947-26-000042
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Prestige Consumer Healthcare Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.